drugset
drugset / Trial / NCT03854305

Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease

NCT03854305 ↗

Phase 2 Completed 93 enrolled Provention Bio, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and safety of oral PRV-6527 in the treatment of moderately to severely active Crohn's disease

Timeline

Start
2018-03-20
Primary completion
2019-08-13
Completion
2019-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject PRV-6527 Unknown — Oral

Indications

Crohn disease